Arca
Skip to content
Tools
Tools

26S proteasome

Complex in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 3
  • In phases 1 to 3: 2
  • Sponsors: 2
  • Genes: 38

Who is on it, and how far along

Every drug ChEMBL records acting on ADRM1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4
  • Protein or peptide 1

Approved3

  • Bortezomib
  • Carfilzomib
  • Ixazomib citrate

Phase 31

  • Ixazomib

Phase 21

  • Oprozomib

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: 26S proteasome inhibitor.
    BortezomibApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor197
    CarfilzomibApprovedAmgenProtein or peptideInhibitor97
    Ixazomib citrateApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor24
    IxazomibPhase 3Takeda Pharmaceuticals USASmall moleculeInhibitor24
    OprozomibPhase 2AmgenSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131BortezomibPhase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.Nov 12, 2026
    SKCD in Early Relapsed/Refractory Multiple MyelomaCarfilzomibPhase 2RecruitingBeijing Chao Yang HospitalNov 12, 2026
    QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II StudyBortezomibPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNov 6, 2026
    To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaBortezomibPhase 3Not yet recruitingKite, A Gilead CompanyOct 29, 2026
    A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleBortezomibPhase 3Not yet recruitingJanssen Research & Development, LLCOct 29, 2026
    Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisBortezomibPhase 3Not yet recruitingRegeneron PharmaceuticalsOct 28, 2026
    Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaBortezomibPhase 2RecruitingTata Memorial CentreOct 23, 2026
    Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaBortezomibPhase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in OncologyOct 22, 2026
    A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaBortezomibPhase 3Not yet recruitingKite, A Gilead CompanyOct 21, 2026
    A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeIxazomib, Ixazomib citratePhase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Oct 19, 2026
    Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaCarfilzomibPhase 3RecruitingCellCentric Ltd.Aug 19, 2026
    A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaCarfilzomibPhase 3RecruitingAbbVieJul 27, 2026
    Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyCarfilzomibPhase 1Not yet recruitingNational Cancer Institute (NCI)Jul 21, 2026
    A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenCarfilzomibPhase 4Not yet recruitingThe First Affiliated Hospital of Soochow UniversityJul 17, 2026
    KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS SyndromeCarfilzomibPhase 2RecruitingShanghai Changzheng HospitalJun 17, 2026
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialCarfilzomibPhase 2RecruitingNational Cancer Institute (NCI)May 26, 2026
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaCarfilzomibPhase 3RecruitingHoffmann-La RocheApr 29, 2026
    SIL as Maintenance Therapy in Multiple MyelomaIxazomib, Ixazomib citratePhase 2Not yet recruitingNavy General Hospital, BeijingDec 20, 2024
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaIxazomib, Ixazomib citratePhase 4RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineFeb 10, 2023
    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisIxazomib, Ixazomib citratePhase 1 / Phase 2Active, not recruitingColumbia UniversityJul 11, 2022
    A Study of NINLARO® in Chinese Adults With Multiple MyelomaIxazomib, Ixazomib citrate—Active, not recruitingTakedaAug 19, 2021
    A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Ixazomib, Ixazomib citratePhase 2Active, not recruitingNantes University HospitalAug 10, 2021
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisIxazomib, Ixazomib citratePhase 1Active, not recruitingNational Cancer Institute (NCI)Apr 19, 2021
    Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and BortezomibIxazomib, Ixazomib citratePhase 2Active, not recruitingTel-Aviv Sourasky Medical CenterMar 10, 2021

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364701, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.